Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Regulation of
ornithine decarboxylase
(
ODC
) is critical to the control of cellular growth, differentiation, and carcinogenesis. A GC-rich region in the
ODC
promoter contains two overlapping protein binding sites that interact to regulate basal level expression in some cell types. A perfect binding motif for
transcription factor Sp1
(CCCCGCCCC) is located at nucleotides -114 to -106 relative to the site of transcriptional initiation, binds strongly to purified Sp1 protein, and forms several complexes when incubated with nuclear extracts. Only one of these complexes is recognized by Sp1-specific antibody. A new protein-binding motif (GCCCCTCCCC, located at -110 to -100) partially overlaps with the Sp1 site and analyses by DNase I protection showed that a new protein ("NF-ODC1") and the Sp1-like proteins interact with the
ODC
promoter in a mutually exclusive manner. Mutation of the NF-ODC1 binding motif strongly enhanced
ODC
promoter strength in some cell types, but had little or no influence in others. The effect of mutating the Sp1 site also varied with cell type. These cell type specificities did not correlate with the levels of Sp1 and NF-ODC1 binding activities in nuclear extracts. These results show that regulation of the
ODC
promoter by the Sp1 family is cell type-specific and modulated by a negative effector that we have termed NF-ODC1.
...
PMID:Complex interactions at a GC-rich domain regulate cell type-dependent activity of the ornithine decarboxylase promoter. 813 14
Altered regulation of
ornithine decarboxylase
(
ODC
) is frequently observed in epidermal tumors. We have shown that the
transcription factor Sp1
is one of the regulators of
ODC
expression and that Sp3 antagonizes this Sp1-mediated activation of
ODC
expression. These results led us to examine the levels and binding activity of Sp1 and Sp3 in nuclear extracts prepared from cultured murine keratinocytes, transformed keratinocyte cell lines and epidermal tumors. Here we show that the Sp1 DNA-binding activity is higher in established keratinocyte cell line extracts than in primary keratinocyte extracts. Sp1 message levels and Sp1 DNA-binding activity was found to be low in 20-week papillomas and high in squamous cell carcinomas. These results suggest that increased levels of Sp1 and enhanced Sp1 DNA binding activity are correlated with epidermal tumor progression. Based on these results, we propose that increased Sp1 DNA binding may augment the proliferative capacity of tumor cells through overexpression of Sp1-responsive genes, possibly including
ODC
.
...
PMID:Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. 1037 37
Evaluation of retinoic acid receptor (RAR) subtype-selective alpha and gamma agonists and antagonists and a retinoid X receptor (RXR) class-selective agonist for efficacy at inhibiting both induction of
ornithine decarboxylase
(
ODC
) by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) in mouse epidermis and rat tracheal epithelial cells and the appearance of papillomas in mouse epidermis treated in the 2-stage tumor initiation-promotion model indicated that (i) RXR class-selective transcriptional agonists, such as MM11246, were not involved in
ODC
inhibition; (ii) RAR-selective agonists that induce gene transcription from RA-responsive elements (RAREs) were active at low concentrations; (iii) RAR-selective antagonists that bind RARs and inhibit AP-1 activation on the collagenase promoter but do not activate RAREs to induce gene transcription were less effective inhibitors; and (iv) RARgamma-selective retinoid agonists were more effective inhibitors of TPA-induced
ODC
activity than RARalpha-selective agonists. These results suggest that RARE activation has a more important role in inhibition of
ODC
activity than RXR activation or AP-1 inhibition and that RARgamma-selective agonists would be the most useful inhibitors of epithelial cell proliferation induced by tumor promoters. The natural retinoid all-trans-RA induced expression of transcription factor ZBP-89, which represses activation of the GC box in the
ODC
promoter by the
transcription factor Sp1
.
...
PMID:Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. 1114 24